Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
Atezolizumab plus bevacizumab and chemotherapy was not to be a cost-effective option for the treatment of metastatic cervical cancer compared to bevacizumab plus chemotherapy.
Authors
- Hongfu Cai (ORCID: https://orcid.org/0000-0002-4923-4882)
- Ling Fang (ORCID: https://orcid.org/0000-0002-3070-1022)
- Zhiwei Zheng (ORCID: https://orcid.org/0000-0002-3938-1862)
- Jingwen Lin
Institutions
- Fujian Medical University (CN)
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-21
- DOI
- https://doi.org/10.3389/fphar.2024.1476256
- Citations
- 4
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.33